JP2022553832A5 - - Google Patents

Info

Publication number
JP2022553832A5
JP2022553832A5 JP2022525903A JP2022525903A JP2022553832A5 JP 2022553832 A5 JP2022553832 A5 JP 2022553832A5 JP 2022525903 A JP2022525903 A JP 2022525903A JP 2022525903 A JP2022525903 A JP 2022525903A JP 2022553832 A5 JP2022553832 A5 JP 2022553832A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
ethoxy
bipyridine
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525903A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657792B2 (ja
JP2022553832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058202 external-priority patent/WO2021091788A1/en
Publication of JP2022553832A publication Critical patent/JP2022553832A/ja
Publication of JP2022553832A5 publication Critical patent/JP2022553832A5/ja
Priority to JP2025050448A priority Critical patent/JP2025109202A/ja
Application granted granted Critical
Publication of JP7657792B2 publication Critical patent/JP7657792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525903A 2019-11-07 2020-10-30 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 Active JP7657792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050448A JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932306P 2019-11-07 2019-11-07
US62/932,306 2019-11-07
PCT/US2020/058202 WO2021091788A1 (en) 2019-11-07 2020-10-30 Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050448A Division JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Publications (3)

Publication Number Publication Date
JP2022553832A JP2022553832A (ja) 2022-12-26
JP2022553832A5 true JP2022553832A5 (https=) 2023-11-07
JP7657792B2 JP7657792B2 (ja) 2025-04-07

Family

ID=75849034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525903A Active JP7657792B2 (ja) 2019-11-07 2020-10-30 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP2025050448A Pending JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050448A Pending JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Country Status (4)

Country Link
US (1) US12479825B2 (https=)
EP (1) EP4054583A4 (https=)
JP (2) JP7657792B2 (https=)
WO (1) WO2021091788A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CA3164117A1 (en) * 2019-12-18 2021-06-24 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
US20230405157A1 (en) * 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof
GB202302618D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
EP4669646A1 (en) 2023-02-23 2025-12-31 Omass Therapeutics Limited MC2R MODULATOR COMPOUNDS
GB202302629D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
JPWO2024237266A1 (https=) * 2023-05-16 2024-11-21
GB202412595D0 (en) 2024-08-28 2024-10-09 Omass Therapeutics Ltd Mc2r modulator compounds
WO2026047337A1 (en) 2024-08-28 2026-03-05 Omass Therapeutics Limited Mc2r modulator compounds
WO2026047334A1 (en) 2024-08-28 2026-03-05 Omass Therapeutics Limited Mc2r modulator compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0151547B1 (ko) 1988-09-06 1998-10-15 노르버트 에이.코통, 롤란드 보레 페닐피리딘 및 이의 제조방법
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
EP1465867A1 (en) 2001-10-09 2004-10-13 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
KR20040058307A (ko) 2001-11-26 2004-07-03 쉐링 코포레이션 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
AU2003230367A1 (en) 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
RS53252B (sr) 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
CN1874777B (zh) 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
CA2735773A1 (en) 2008-09-02 2010-03-11 Neurosearch A/S Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
PL2344474T3 (pl) 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
WO2012163354A1 (en) 2011-05-31 2012-12-06 Linak A/S Actuator
FR3017867A1 (fr) 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
WO2018003962A1 (ja) 2016-06-30 2018-01-04 国立研究開発法人理化学研究所 新規化合物又はその薬理学的に許容される塩
WO2019014460A1 (en) 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. MOLECULES ENHANCING EAAT2
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CA3164117A1 (en) 2019-12-18 2021-06-24 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
US11565011B2 (en) 2020-09-18 2023-01-31 Ncr Corporation Sterilizing media cassette
US20230405157A1 (en) 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof

Similar Documents

Publication Publication Date Title
JP2022553832A5 (https=)
JP2007508346A5 (https=)
RU2497813C2 (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
JP2007531752A5 (https=)
JP2010513304A5 (https=)
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2022531801A5 (https=)
JP2023523438A5 (https=)
JP2015503529A5 (https=)
RU2016108753A (ru) Ингибиторы ферментов
JP2007519735A5 (https=)
CA2476343A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
JP2011518836A5 (https=)
JP2010513444A5 (https=)
JP2010502615A5 (https=)
JP2017522346A5 (https=)
RU2010146384A (ru) Пирролидиноновые активаторы глюкокиназы
JP2009536196A5 (https=)
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
JP2006500369A5 (https=)
JP2006503081A5 (https=)
JP2020526547A5 (https=)
JP2007501831A5 (https=)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2019529445A5 (https=)